MARKET

EVFM

EVFM

Evofem
NASDAQ

Real-time Quotes | Nasdaq Last Sale

6.46
-0.17
-2.56%
Closed 16:00 02/21 EST
OPEN
6.63
PREV CLOSE
6.63
HIGH
6.65
LOW
6.31
VOLUME
79.37K
TURNOVER
--
52 WEEK HIGH
7.50
52 WEEK LOW
3.190
MARKET CAP
114.75M
P/E (TTM)
-2.5688
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of EVFM and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average EVFM stock price target is 12.00 with a high estimate of 20.00 and a low estimate of 8.00.

EPS

EVFM News

More
  • 3 Monster Growth Stocks That Can Charge Forward in 2020
  • TipRanks · 6d ago
  • Hedge Funds Have Never Been This Bullish On Evofem Biosciences, Inc. (EVFM)
  • Insider Monkey · 12/22/2019 22:32
  • U.S. FDA Acknowledges Receipt Of Evofem Biosciences' New Drug Application Resubmission For Amphora For The Prevention Of Pregnancy
  • Benzinga · 12/18/2019 12:31
  • U.S. FDA Acknowledges Receipt of Evofem Biosciences' New Drug Application Resubmission for Amphora® for the Prevention of Pregnancy
  • PR Newswire · 12/18/2019 12:30

Industry

Pharmaceuticals
+0.60%
Pharmaceuticals & Medical Research
+0.54%

Hot Stocks

Symbol
Price
%Change
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%

About EVFM

Evofem Biosciences Inc, formerly Neothetics, Inc., is a clinical-stage specialty biopharmaceutical company. The Company develops products to address unmet needs in women's sexual and reproductive health. The Company’s product Amphora, is a Multipurpose Vaginal pH Regulator (MVP-R) designed to regulate vaginal pH to within the normal range of 3.5 to 4.5 even in the presence of semen. This maintains an acidic environment which is inhospitable to sperm as well as certain viral and bacterial pathogens associated with sexually transmitted infections. Amphora is used to prevent urogenital chlamydia and gonorrhea in women. The Company is in the second Phase III clinical trial of Amphora for prevention of pregnancy (AMP002). The Company is currently designing a Phase IIb trial for its second product candidate, a MVP-R to reduce the recurrence of bacterial vaginosis.
More

Webull offers kinds of Evofem Biosciences Inc stock information, including NASDAQ:EVFM real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, EVFM stock news, and many more online research tools to help you make informed decisions.